A Phase 1/2 Study of the Menin Inhibitor Revumenib With the CELMod Mezigdomide in Relapsed/Refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged Acute Leukemias
Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.
Eligibility
- Age range
- 12+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participant must be ≥ 12 years of age at the time of signing the informed consent form (ICF). * Participant must weigh at least 40 kg * Participant is willing and able to adhere to the study visit schedule and other protocol requirements. * Participant has relapsed/refractory acute leukemia defined acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia after as failure of at least 1 prior line of therapy (can be either primary refractory disease or progression during or after treatment) * Participant has confirmed acute leukemia with dete…
Interventions
- DrugRevumenib
Revumenib is a novel menin inhibitor
- DrugMezigdomide
Mezigdomide (CC-92480) is an investigational CELMoD.
Locations (10)
- City of Hope Cancer Center (Data collection only)Duarte, California
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison, New York